A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B
Latest Information Update: 28 Dec 2023
At a glance
- Drugs Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 14 Nov 2023 Results of pooled data (n=1298) assessing to characterize factors associated with virologic failure after 8 years of treatment in a cohort of patients enrolled from GS-US-320-0108 and GS-US-320-0110 trials, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
- 14 Nov 2023 Results assessing annual resistance surveillance from years 3 through 8 of tenofovir alafenamide treatment in patients from studies GS-US-320-0108 and Study GS-US-320-0110, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
- 14 Nov 2023 Results of pooled analysis from two phase 3 studies assessing the safety of TAF, including in patients switched from TDF to TAF, who were considered to be at risk for adverse bone and/or renal effects from TDF based on EASL guidelines presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.